Media
| Press Releases
Results of the Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Comp...
Results of the Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Compared with Eplerenone...
Aug 06, 2021
Announcement of Chief Financial Officer Appointment
Announce the appointment of James Fang as Chief Financial Officer of KBP Biosciences, effective on J...
Jul 30, 2021
Announcement of Chief Operating Officer Appointment
Announce the appointment of Dr. Julia Yang as Chief Operating Officer of KBP Biosciences.
Jul 30, 2021
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduct...
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic sys...
Jun 22, 2021
KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 ...
KBP-5074 Achieves 10.1 mmHg reduction in systolic blood pressure (SBP) at 0.5mg dose compared to pla...
Dec 07, 2020
KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074
KBP-5074 Being Evaluated for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney D...
Aug 11, 2020
KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript f...
KBP-5074 is a highly-selective non-steroidal mineralocorticoid receptor antagonist with potentially ...
Jun 30, 2020
KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in se...
Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or.....
May 21, 2020
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074
KBP-5074, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Under Evaluation for the Treatmen.....
May 20, 2020
KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Ag...
Potency demonstrated across geographically diverse strains including antibiotic-resistant isolates.....
Apr 28, 2020